CareFusion (NYSE: CFN) was upgraded by analysts at CLSA from an “outperform” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The firm currently has a $30.00 price target on the stock.
A number of other firms have also recently commented on CFN. Analysts at Credit Agricole upgraded shares of CareFusion from an “outperform” rating to a “buy” rating in a research note to investors on Thursday. Separately, analysts at Piper Jaffray (NYSE: PJC) initiated coverage on shares of CareFusion in a research note to investors on Wednesday, May 16th. They set an “overweight” rating on the stock. Finally, analysts at Raymond James (NYSE: RJF) initiated coverage on shares of CareFusion in a research note to investors on Wednesday, April 25th. They set a “strong-buy” rating on the stock.
CareFusion traded up 0.48% on Thursday, hitting $24.88. CareFusion has a 1-year low of $22.01 and a 1-year high of $29.19. The company has a market cap of $5.521 billion and a price-to-earnings ratio of 20.26.
CareFusion last released its earnings data on Thursday, May 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.04. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. Analysts expect that CareFusion will post $0.40 EPS next quarter.
CareFusion Corporation (CareFusion) is a global medical technology company. The Company offers product lines in the areas of IV infusion, medication and supply dispensing, respiratory care, infection prevention and surgical instruments.